Cerus (CERS) Stock Price, News & Analysis

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Cerus in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" CERS shares.
View CERS analyst ratings or view top-rated stocks.

3 Wall Street analysts have issued twelve-month target prices for Cerus' stock. Their CERS share price targets range from $2.50 to $5.00. On average, they predict the company's stock price to reach $3.50 in the next year. This suggests a possible upside of 109.0% from the stock's current price.
View analysts price targets for CERS or view top-rated stocks among Wall Street analysts.

Cerus' stock was trading at $2.16 at the beginning of 2024. Since then, CERS stock has decreased by 22.5% and is now trading at $1.6750.
View the best growth stocks for 2024 here.

Cerus saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 5,880,000 shares, an increase of 16.0% from the March 15th total of 5,070,000 shares. Based on an average daily trading volume, of 1,620,000 shares, the short-interest ratio is presently 3.6 days.
View Cerus' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our CERS earnings forecast.

Cerus will be holding an earnings conference call on Thursday, May 2nd at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link.

Cerus Co. (NASDAQ:CERS) announced its earnings results on Tuesday, March, 5th. The biotechnology company reported ($0.01) EPS for the quarter, meeting the consensus estimate of ($0.01). The biotechnology company had revenue of $46.77 million for the quarter, compared to analyst estimates of $46.80 million. Cerus had a negative trailing twelve-month return on equity of 67.17% and a negative net margin of 23.98%.

ETFs with the largest weight of Cerus (NASDAQ:CERS) stock in their portfolio include ARK Genomic Revolution ETF (ARKG).ARK Innovation ETF (ARKK).

Cerus updated its FY 2024 earnings guidance on Wednesday, March, 6th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $172.0 million-$175.0 million, compared to the consensus revenue estimate of $185.9 million.

15 employees have rated Cerus Chief Executive Officer William M. (Obi) Greenman on Glassdoor.com. William M. (Obi) Greenman has an approval rating of 35% among the company's employees. This puts William M. (Obi) Greenman in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Cerus investors own include Rite Aid (RAD), SCYNEXIS (SCYX), Alibaba Group (BABA), Inovio Pharmaceuticals (INO), OPKO Health (OPK), Pfizer (PFE), Immunomedics (IMMU), Exelixis (EXEL), Novavax (NVAX) and NVIDIA (NVDA).

Cerus' stock is owned by a number of retail and institutional investors. Top institutional investors include Sumitomo Mitsui Trust Holdings Inc. (4.28%), Wasatch Advisors LP (3.47%) and Bouvel Investment Partners LLC (0.15%). Insiders that own company stock include Ann Lucena, Carol Moore, Chrystal Jensen, Chrystal Menard, Daniel N Swisher Jr, Eric Bjerkholt, Gail Schulze, Kevin Dennis Green, Laurence M Corash, Richard J Benjamin, Vivek K Jayaraman and William Mariner Greenman.
View institutional ownership trends.

Shares of CERS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.